Medscape

Osimertinib's Benefits in NSCLC Can Extend Beyond First Line

Data from the COMPEL trial support extending osimertinib (Tagrisso, AstraZeneca) therapy to patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progress on first-line treatment ...
Nature

Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial

Chemo-immunotherapy is the current first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), but survival benefits are modest. We aimed to evaluate the safety, antitumor ...
Nasdaq

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or ...

RARITAN, N.J., Feb. 19, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational ...